Abstract
Vector-borne diseases like malaria, dengue, chikungunya, Japanese encephalitis, Zika and others claim millions of lives across the globe annually, and as such their control has become an ardent necessity. Past attempts over the decades have introduced vector control through chemical, biological and environmental means. However, these measures, already in place, failed to completely bring down the mortality rates from vector-borne diseases, most of which lack a vaccine to prevent epidemics or even a specific antidote to treat patients. The modern development of technologies such as the release of insects carrying a dominant lethal (RIDL) gene system, an example of transgenesis; the Wolbachia-based cytoplasmic incompatibility inducing infertility in female insects, an example of paratransgenesis; and the revolutionary gene drive (CRISPR/Cas9) technology, has their roots in the sterile insect technology (SIT), which worked by creating sterilized males through irradiation to compete with their wild counterparts and subsequently mate with females in nature to produce infertile eggs; a technology meant to gradually and finally exterminate the vector population in nature. These technologies have shown great promise, albeit many imperfections, particularly regarding acceptance by the concerned societies. As far as vector control is concerned, we have attempted to simplify their definitions for the common man so that the intricate scientific jargon about these technologies do not instill any fear or doubts to the end users.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carvalho DO, McKemey AR, Garziera L et al (2015) Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl Trop Dis 9(7):e0003864
Gould EA, Higgs S (2009) Impact of climate change and other factors on emerging arbovirus diseases. Trans R Soc Trop Med Hyg 103(2):109–121
Harris AF, McKemey AR, Nimmo D et al (2012) Successful suppression of a field mosquito population by sustained release of engineered male mosquitoes. Nat Biotechnol 30(9):828–830
Marshall JM (2010) The Cartagena protocol and genetically modified mosquitoes. Nat Biotechnol 28:896–897
Marshall JM (2011) The Cartagena protocol in the context of recent releases of transgenic and Wolbachia-infected mosquitoes. Asia Pac J Mol Biol Biotechnol 19:93–100
Marshall JM, Akbari OS (2018) Can CRISPR-based gene drive be confined in the wild? A question for molecular and population biology. ACS Chem Biol 13:424–430
Patil PB, Niranjan Reddy BP, Gorman K et al (2015) Mating competitiveness and life-table comparisons between transgenic and Indian wild-type Aedes aegypti L. Pest Manag Sci 71(7):957–965
Patil PB, Gorman Kevin J, Dasgupta Shaibal K, Seshu Reddy KV, Barwale Shirish R, Zehr Usha B (2018) Self-limiting OX513A Aedes aegypti demonstrate full susceptibility to currently used insecticidal chemistries as compared to Indian wild-type Aedes aegypti. Psyche:7814643, 7 p. https://doi.org/10.1155/2018/7814643
Tyagi BK (2020) Mosquito hunters: a history of hostilities against man’s deadliest foe—the mosquito—since 1881. Scientific Publishers, Jodhpur, 474 pp
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chatterjee, R., Bhattacharya, S., Tyagi, B.K. (2021). Perspectives into Genetic Manipulations for Control of Dengue Vector (Aedes aegypti Linnaeus, 1762) with Reference to Progress in Indian Experiments. In: Tyagi, B.K. (eds) Genetically Modified and other Innovative Vector Control Technologies. Springer, Singapore. https://doi.org/10.1007/978-981-16-2964-8_7
Download citation
DOI: https://doi.org/10.1007/978-981-16-2964-8_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-2963-1
Online ISBN: 978-981-16-2964-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)